Wegovy (semaglutide), a GLP-1 agonist, aids weight loss and treats obesity, cardiovascular risk, and MASH. Common side effects include nausea (44%), vomiting (24%), diarrhea (30%), constipation (24%), abdominal pain (20%), headache (14%), fatigue (11%), dizziness, and injection site reactions. Hypoglycemia is a risk in diabetic patients. Serious side effects include thyroid tumors, severe gastroparesis, pancreatitis, […]